Table of Contents

Research Articles

• Research Articles

  Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism

  Patrik Sundström, Hanna Stenstad, Veronica Langenes, Filip Ahlmanner, Lisa Theander, Tapuka Gordon Ndah, Kamilla Fredin, Lars Börjesson, Bengt Gustavsson, Jérémy Bastid and Marianne Quiding-Järbrink

  Cancer Immunol Res March 1 2016 4 (3) 183-193; DOI:10.1158/2326-6066.CIR-15-0050

  
  

  Regulatory T cells suppress many effector T-cell functions. Tregs from patients with colon cancer were found to inhibit transendothelial migration of conventional T cells, perhaps explaining the paucity of effector T cells within tumors.

• Research Articles | Free Article

  PD-1 Blockade Expands Intratumoral Memory T Cells

  Antoni Ribas, Daniel Sanghoon Shin, Jesse Zaretsky, Juliet Frederiksen, Andrew Cornish, Earl Avramis, Elizabeth Seja, Christine Kivork, Janet Siebert, Paula Kaplan-Lefko, Xiaoyan Wang, Bartosz Chmielowski, John A. Glaspy, Paul C. Tumeh, Thinle Chodon, Dana Pe'er and Begoña Comin-Anduix

  Cancer Immunol Res March 1 2016 4 (3) 194-203; DOI:10.1158/2326-6066.CIR-15-0210

  
  

  Tumor biopsies from patients treated with antibodies to PD-1 showed that therapy altered tumor composition. T cells, B cells, and myeloid-derived suppressor cells were increased, and patients who responded to anti–PD-1 therapy had increased memory CD8⁺ T cells.

• Research Articles

  Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

  Qiong J. Wang, Zhiya Yu, Kayla Griffith, Ken-ichi Hanada, Nicholas P. Restifo and James C. Yang

  Cancer Immunol Res March 1 2016 4 (3) 204-214; DOI:10.1158/2326-6066.CIR-15-0188

  
  

  This study identifies HLA-A11*01–restricted T-cell receptors (TCRs) that specifically target mutated KRAS, which is an oncogenic driver mutation found in many types of cancers. These TCRs have antitumor activity and thus show potential for clinical use in multiple cancers.

• Research Articles | AuthorChoice

  Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

  Yaewon Yang, Okjae Lim, Tae Min Kim, Yong-Oon Ahn, Hana Choi, Hyejin Chung, Bokyung Min, Jung Hyun Her, Sung Yoo Cho, Bhumsuk Keam, Se-Hoon Lee, Dong-Wan Kim, Yu Kyeong Hwang and Dae Seog Heo

  Cancer Immunol Res March 1 2016 4 (3) 215-224; DOI:10.1158/2326-6066.CIR-15-0118

  
  

  Completely allogeneic NK cells could provide a ready source of antitumor activity. This preliminary clinical trial shows that such cells are well tolerated and have potential benefits for cancer patients by upregulating the host immune responses against cancer.

• Research Articles | AuthorChoice

  Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer

  Darshil T. Jhaveri, Min-Sik Kim, Elizabeth D. Thompson, Lanqing Huang, Rajni Sharma, Alison P. Klein, Lei Zheng, Dung T. Le, Daniel A. Laheru, Akhilesh Pandey, Elizabeth M. Jaffee and Robert A. Anders

  Cancer Immunol Res March 1 2016 4 (3) 225-233; DOI:10.1158/2326-6066.CIR-15-0200-T

  
  

  Serum samples from patients in a phase II pancreas cancer vaccine clinical trial were subjected to quantitative proteomics. Three highly induced proteins in the pancreas after vaccination became targets of antibodies. Patients harboring these antibodies had improved clinical outcomes.

• Research Articles

  Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator

  Yutaka Kurebayashi, Katsura Emoto, Yuichiro Hayashi, Ikuo Kamiyama, Takashi Ohtsuka, Hisao Asamura and Michiie Sakamoto

  Cancer Immunol Res March 1 2016 4 (3) 234-247; DOI:10.1158/2326-6066.CIR-15-0214

  
  

  Lung cancer is a complex disease with variable outcomes. Immune cells from 114 cases were quantified immunohistochemically, identifying four immunosubtypes of lung adenocarcinoma (CD8, mast cell, macrophage/DC, and plasma cell) that could potentially be useful for therapy selection.

• Research Articles

  Immunotherapy against Metastatic Melanoma with Human iPS Cell–Derived Myeloid Cell Lines Producing Type I Interferons

  Azusa Miyashita, Satoshi Fukushima, Satoshi Nakahara, Yosuke Kubo, Aki Tokuzumi, Junji Yamashita, Jun Aoi, Miwa Haruta, Satoru Senju, Yasuharu Nishimura, Masatoshi Jinnin and Hironobu Ihn

  Cancer Immunol Res March 1 2016 4 (3) 248-258; DOI:10.1158/2326-6066.CIR-15-0096

  
  

  Human myeloid cell lines derived from iPS cells were genetically modified to express type I IFNs. These cells durably inhibited the growth of human melanoma in xenograft models by infiltrating tumors and providing local antitumor effects.

• Research Articles

  CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains

  Satoshi Shiina, Masasuke Ohno, Fumiharu Ohka, Shunichiro Kuramitsu, Akane Yamamichi, Akira Kato, Kazuya Motomura, Kuniaki Tanahashi, Takashi Yamamoto, Reiko Watanabe, Ichiro Ito, Takeshi Senga, Michinari Hamaguchi, Toshihiko Wakabayashi, Mika K. Kaneko, Yukinari Kato, Vidyalakshmi Chandramohan, Darell D. Bigner and Atsushi Natsume

  Cancer Immunol Res March 1 2016 4 (3) 259-268; DOI:10.1158/2326-6066.CIR-15-0060

  
  

  The glioblastoma subtypes with the worst prognoses often bear podoplanin. T cells expressing a chimeric antigen receptor that targets podoplanin were specific and effective against PDPN-positive glioblastoma cells in vitro and increased survival time in a mouse model.